4 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophyautonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathyActive, not recruitingPhase 22026-10-09NCT06568237
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseParkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathyRecruitingPhase 32026-10-06NCT07174310
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear PalsyFrontotemporal Lobar Degeneration, Neurologic Manifestations, Ocular Motility Disorders, Pathological Conditions, Signs and Symptoms, Pick disease, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, cranial nerve neuropathy, dementia, eye disorder, frontotemporal dementia, movement disorder, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, psychiatric disorder, tauopathyRecruitingPhase 32026-07-29NCT07498426
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)Disease Attributes, Disease Progression, Neurologic Manifestations, Ocular Motility Disorders, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, cranial nerve neuropathy, eye disorder, movement disorder, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, progressive supranuclear palsy, tauopathyActive, not recruitingPhase 22025-10-15NCT06355531